购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

DDR1-IN-2

Rating icon 很棒
产品编号 T5402Cas号 1429617-90-2
别名 DDR1 inhibitor 7rh

DDR1-IN-2 (DDR1 inhibitor 7rh) 是盘状结构域受体 1 抑制剂 (IC50:13.1 nM),对 DDR2 的抑制作用相对较弱 (IC50:203 nM)。

DDR1-IN-2
TargetMol

为众多的药物研发团队赋能,

让新药发现更简单!

DDR1-IN-2

Rating icon 很棒
纯度: 97.51%
产品编号 T5402 别名 DDR1 inhibitor 7rhCas号 1429617-90-2

DDR1-IN-2 (DDR1 inhibitor 7rh) 是盘状结构域受体 1 抑制剂 (IC50:13.1 nM),对 DDR2 的抑制作用相对较弱 (IC50:203 nM)。

规格价格库存数量
1 mg
¥ 523
现货
5 mg
¥ 1,230
现货
10 mg
¥ 1,990
现货
25 mg
¥ 3,990
现货
50 mg
¥ 5,680
现货
100 mg
¥ 7,930
现货
500 mg
¥ 15,900
现货
1 mL x 10 mM (in DMSO)
¥ 1,480
现货
大包装 & 定制
加入购物车
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
实验操作小课堂
常见问题解答
产品的溶解度是多少?
建议您先查询TargetMol官网、陶术官网,看该抑制剂的产品介绍,找到溶解度信息。如果没有相应信息,建议联系技术对该化合物的溶解度进行测定。
加药后检测结果没有作用,是不是产品质量有问题?
产品质量没有问题,都是经过两次严格质检的,HNMR确定产品结构,HPLC确定化合物纯度。同一个抑制剂由于实验材料(细胞、动物)的不同,IC50 和实验效果也是不一样的,不能照搬文献报道的方法,应该根据自己的实验设立浓度梯度,得到一个最适合的浓度。
动物实验常用溶解方法?
首先,您需要确认给药剂量、给药方式。对于具体的产品,优先找引用我们产品的文献里的使用方法,再找其他文献里的配方。 如果没有相关的文献,且该化合物的 DMSO 溶解度比较好,我们推荐通用配方: 10% DMSO+40% PEG300+5% Tween-80+45% Saline/PBS/ddH2O。溶剂依次加入,尽量溶解后再加入下一个溶剂。正常鼠建议 DMSO 浓度在 10% 以下,裸鼠体弱鼠等配方的 DMSO 浓度建议在 2% 以下,根据溶液是否澄清,助溶剂 PEG300、Tween-80 的比例可以适当调整。如果有其他助溶剂也可以使用。 以上配方仅供参考,体内配方并不是绝对的,需要根据不同情况进行调整。建议先取少量化合物测试配方,再进行大量配制。配完也可以再使用超声、加热等方式助溶,看看能不能澄清一点。 腹腔注射对粉末的溶解度要求比较高,建议购买盐形式化合物。如果给药剂量比较大,也有报道使用混悬液进行腹腔给药的。 对于灌胃给药,且剂量比较大的情况下,建议用 0.5% CMC-Na 配置成均匀混悬液进行给药。
超声久了会不会对化合物的结构有影响?
建议以较低频率对化合物进行超声,不会对化合物的结构造成影响。
抑制剂能否用于动物实验?
可以的,我们的抑制剂都可以用于动物/体内实验。但有些化合物还没有用于动物实验的文献,这种情况下,建议您先做预实验,确保研究的可行性。
查看更多

"DDR1-IN-2"的相关化合物库

选择批次:
纯度:97.51%
联系我们获取更多批次信息

产品介绍

生物活性
产品描述
DDR1-IN-2 (DDR1 inhibitor 7rh) (DDR1 inhibitor 7rh) is a potent, selective, ATP-competitive Discoidin domain receptor 1 (DDR1) inhibitor (IC50: 6.8 nM in cell-free kinase assays).
靶点活性
DDR1:6.8 nM (cell free), DDR2:101.4 nM (cell free)
体外活性
DDR1-IN-2 inhibited the enzymatic activity of DDR1, with IC50 values of 6.8 nM, but were significantly less potent in suppressing the kinase activities of DDR2, Bcr-Abl, and c-Kit. It bound with DDR1 with a Kd value of 0.6 nM, while it was significantly less potent to the other 455 kinases tested. It also potently inhibited the proliferation of cancer cells expressing high levels of DDR1 and strongly suppressed cancer cell invasion, adhesion, and tumorigenicity [1]. Pharmacologic inhibition of DDR1 with an ATP-competitive orally available small-molecule kinase inhibitor (DDR1-IN-2) abrogated collagen-induced DDR1 signaling in pancreatic tumor cells and consequently reduced colony formation and migration [2].
体内活性
DDR1-IN-2 possessed good PK profiles, with oral bioavailabilities of 67.4% [1]. The inhibition of DDR1 with DDR1-IN-2 showed striking efficacy in combination with chemotherapy in orthotopic xenografts and autochthonous pancreatic tumors where it significantly reduced DDR1 activation and downstream signaling, reduced primary tumor burden, and improved chemoresponse [2].
激酶实验
The functional assays of compounds on the kinase activities of c-kit and Abl were determined using the FRET-based Z'-Lyte assay system according to the manufacturer's instructions. Tyrosine 2 Peptide was used as Abl substrate and Ser/Thr 6 peptide was used as the substrate for c-kit. The reactions were carried out in 384-well plates in a 10 μl of reaction volume with an appropriate amount of kinases in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. The reactions were incubated 1 hour at room temperature in the presence of 2 μM of substrate with 10 μM of ATP (for Abl1 assays) or 300 μM of ATP (kit assay) and in the presence of various concentrations of the compounds. The development reagent was then added for further 2 hours room temperature incubation followed by the addition of stop solution. Fluorescence signal ratio of 445 nm (Coumarin)/520 nm (fluorescin) was examined on EnVision Multilabel Reader. The effects of compounds on the kinases DDR1 and DDR2 were assessed by using a LanthaScreen Eu kinase activity assay technology. Kinase reactions are performed in a 10 μL volume in low-volume 384-well plates. The kinases in reaction buffer consist of 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, and 1 mM EGTA, the concentration of Fluorescein-Poly GAT Substrate in the assay is 100 nM, Kinase reactions were initiated with the addition of 100 nM ATP in the presence of serials of dilutions of compounds. The reactions were allowed to proceed for 1 hour at room temperature before a 10 μL preparation of EDTA (20 mM) and Eu-labeled antibody (4 nM) in TR-FRET dilution buffer are added. The final concentration of antibody in the assay well is 2 nM, and the final concentration of EDTA is 10 mM. The plate is allowed to incubate at room temperature for one more hour before the TR-FRET emission ratios of 665 nm/340 nm were acquired on a PerkinElmer EnVision Multilabel Reader [1].
细胞实验
Adherent Cells were plated in 96-well culture plates with a cell density of 3000-4000 cells/well and treated with indicated compounds by adding 100μL medium containing compounds of various concentrations on the second day. After 72-hour's treatment, MTT was added to each well and incubated for additional 4-5 hours, and the absorbance was measured on a microplate reader at 570nm. Cell growth inhibition was evaluated as the ratio of the absorbance of the sample to that of the control. The results are representative of at least 4 independent experiments [1].
动物实验
Compounds 7rh and 7rj were dissolved in mixed solvents (DMSO : EtOH:Cremophor EL : H2O = 2 : 4 : 4 : 90) as clear solution. The final concentrations were 2.5 mg/mL. Sprague Dawley (SD) rats (male, 4 animals per group) weighted 180~220g were injected intravenously or administrated orally at doses of 5 mg/kg (i.v.) or 25mg/kg (p.o.), respectively. After dose administration, 0.3 mL of the orbital blood was taken at 2.0 min, 10.0 min, 30.0 min, 1.0 h, 2.0 h, 3.0 h, 4.0 h, 6.0 h, 8.0 h, 12.0 h, 21.0 h, 24.0 h, 30.0 h, 36.0 h, 48.0 h, and 72.0 h. Samples were stored at -70℃ until shipment to the analytical laboratory and tested by HPLC/MS using propranolol as internal standard to measure the compound concentration in the blood [1].
别名DDR1 inhibitor 7rh
化学信息
分子量546.59
分子式C30H29F3N6O
CAS No.1429617-90-2
SmilesCCc1ccc(cc1C#Cc1cnc2ccnn2c1)C(=O)Nc1cc(CN2CCN(C)CC2)cc(c1)C(F)(F)F
密度no data available
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
DMSO: 18.33 mg/mL (33.54 mM), Sonication is recommended.
溶液配制表
DMSO
1mg5mg10mg50mg
1 mM1.8295 mL9.1476 mL18.2952 mL91.4762 mL
5 mM0.3659 mL1.8295 mL3.6590 mL18.2952 mL
10 mM0.1830 mL0.9148 mL1.8295 mL9.1476 mL
20 mM0.0915 mL0.4574 mL0.9148 mL4.5738 mL

SCI 文献

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60%Saline/PBS/ddH2O, 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLSaline/PBS/ddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

参考文献

关键词

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

Related Tags: buy DDR1-IN-2 | purchase DDR1-IN-2 | DDR1-IN-2 cost | order DDR1-IN-2 | DDR1-IN-2 chemical structure | DDR1-IN-2 in vivo | DDR1-IN-2 in vitro | DDR1-IN-2 formula | DDR1-IN-2 molecular weight